Paediatric medicine issues and gaps from healthcare workers point of view: survey results and a narrative review from the global accelerator for paediatric formulations project.

Autor:	Barbieri E; Division of Pediatric Infectious Diseases, Department of Women's and Children's Health, University of Padova, Padova, Italy.; Penta-Child Health Research, Padova, Italy., Minotti C; Division of Pediatric Infectious Diseases, Department of Women's and Children's Health, University of Padova, Padova, Italy., Cavagnis S; Penta-Child Health Research, Padova, Italy., Giaquinto C; Division of Pediatric Infectious Diseases, Department of Women's and Children's Health, University of Padova, Padova, Italy.; Penta-Child Health Research, Padova, Italy., Cappello B; Department of Health Products Policy and Standards, World Health Organization, Geneva, Switzerland., Penazzato M; WHO Research for Health Department, World Health Organization, Geneva, Switzerland., Lallemant M; Penta-Child Health Research, Padova, Italy.; Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.
Jazyk:	angličtina
Zdroj:	Frontiers in pharmacology [Front Pharmacol] 2023 Jul 17; Vol. 14, pp. 1200848. Date of Electronic Publication: 2023 Jul 17 (Print Publication: 2023).
DOI:	10.3389/fphar.2023.1200848
Abstrakt:	The WHO Model List of Essential Medicines for Children (EMLc) has not been systematically revised in the last few years. We conducted a survey addressed to healthcare professionals prescribing, preparing, or administering medicines to children and a narrative review to identify problematic paediatric formulations or missing medicines in all therapeutic fields to inform the review of the EMLc in 2023. A total of 285 physicians (63%), 28 nurses (6%) and 142 pharmacists (31%), mostly working in the hospital setting, reported at least one problematic medicine. 290 medicines were reported as missing (completely or the child-appropriate formulation). The top three most mentioned were ciprofloxacin together with phenobarbital and omeprazole. 387 medicines were reported as problematic (34% were oral liquid formulations, 34% tablets, 18% parenteral preparations. Mostly of the products were antibacterials (27%), cardiovascular medicines (11%) and antivirals (11%). The obtained responses show the perspective of healthcare workers working around the world, particularly in the European region (25%), in the African region (24%), and in the Region of the Americas (19%), with limited representation from Northern Africa and the Middle East. Our results need to be analysed with the outputs of other ongoing works before specific products can enter the WHO-hosted Global Accelerator for Paediatric formulations network prioritisation process. Efforts to develop appropriate formulations for children should be accelerated so that the uncertainties associated with off-label drug preparation and use are minimised, and therapeutic benefits are optimised. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Barbieri, Minotti, Cavagnis, Giaquinto, Cappello, Penazzato and Lallemant.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu